Trial Profile
A 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthritis (sJIA); with a 92-week single arm open-label extension to examine the long term use of tocilizumab, followed by a 3 year open label continuation of the study to examine the long term use of tocilizumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms TENDER
- Sponsors Roche
- 16 Nov 2020 Results (n=286) of meta-analysis of 5 studies assessing relative efficacy and safety of canakinumab, anakinra, tocilizumab, and rilonacept in patients with active sJIA, published in the International Journal of Clinical Pharmacology and Therapeutics.
- 01 Mar 2019 France was planned location as per European Clinical Trials Database record.
- 01 Mar 2019 Denmark, Sweden were planned locations as per ClinicalTrials.gov record.